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reflects a preference on behalf of the decision maker. Reality does not always match 
the ideal of a fixed threshold.
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Objectives: South America (SA) is a continent with 400 million people and occu-
pies 12% of the world’s territory. It is composed by 12 countries and 6.75% of its 
population is below the poverty line, as defined by UN. The proper distribution of 
financial health resources, through an HTA process in public systems is potentially 
essential to improve the quality of health care expenditure. The objective of this 
study is to understand the incorporation process of new health technologies and 
compare the general health status in each country, regarding the Objectives of 
the Millennium (OM). MethOds: A public data collection was performed in offi-
cial sources linked to UN, to governments of SA and the Unión de las Naciones 
Suramericana (UNASUR). Results: The public health financing in SA countries 
was between 2.43% and 6.20% of the GDP. An HTA process in an institutionalized 
and specialized form is in place in only 3 countries (Argentina, Brazil and Peru). 
Bolivia, Chile, Colombia, Paraguay and Venezuela do not have a specialized HTA 
process and the other four countries have no HTA process at all. Regarding the OM 
the decrease in child mortality, increase in vaccination, increase in malaria and 
tuberculosis treatments are among the closest to be achieved in all countries. There 
is a linear positive correlation of OM with the Human Development Index and with 
the percentage of GDP invested in public health but not with having a HTA process 
in place. cOnclusiOn: At this moment, there is no evidence that an HTA process 
in place helps SA countries to achieve the OM.
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Objective: The Balduzzi law (189/2012) introduced several changes aimed at pro-
moting the country’s development through a higher level of health protection and 
at bridging the gap left by the rationing of health care resource from the Spending 
Review (135/2012). Reducing the time to drug market access is one of the main pur-
poses. The aim of the research is a critical analysis of this law to understand its actual 
and future impact on the health care scenario. MethOds: An evaluation of the laws 
issued in the last three years that aimed at regulating the drug market was carried out. 
To build a future scenario analysis, we focused our attention on the Balduzzi law and 
two of its articles (11 and 12) and on the new drugs approved by AIFA and commercial-
ized under the new regulation. Results: The changes that will have a major impact 
on the drug market are: the allocation of the medicines approved under centralized 
procedure in the non-negotiated C Class within 60 days from the publication in the 
Official Gazzette of the European Union and the direct placement of generics and bio-
similars in the reimbursement class of the originator without any price negotiation. As 
of now, a total number of 49 drugs have been included in the non-negotiated C Class, 
within this new group there are 15 first drug authorizations. cOnclusiOn: The new 
reform can be potentially an interesting innovation to speed up market access, though 
the impact of including new drugs in the C class (at patient charge) before the price 
negotiation is still under debate. The increased competitiveness coming from having 
a faster introduction in the market of generics/biosimilars could lead to important 
savings for the National Healthcare System over the next years.
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A large number of factors point to an unavoidable rise in health care expenditure to 
13%-18% of Europe’s GDP by 2030, even with policy interventions or budget caps that 
aim to counterbalance these pressures. This growth in health care costs need not be 
undesirable especially so when higher spending on health care leads to improved health 
care quality and life expectancy. Therefore, the challenge is not “how do we reverse the 
growth of health care costs?” but “how can we best deploy the increasing resources spent 
on health care to create optimal benefits for the European population?” Health R&D is 
the key to being able to respond to this dilemma. Increased investment in R&D leads to 
improved health outcomes, long term efficiency gains, better productivity and high eco-
nomic yields. However, the outlook for Europe is not as positive as it could be. Recently, 
there has been a stagnation or even decline in European private and public investment 
in R&D, which is in sharp contrast with the much higher investments in the US. Private 
biopharmaceutical investments in health R&D, which are double the size of public health 
R&D, in 2011 actually decreased in absolute terms. Public R&D investments declined or 
stagnated in most European countries and will be further under pressure in the near 
future due to public budget deficits. Janssen commissioned the Deloitte European Center 
on Health Economics and Outcomes Research to set out the arguments in support of 
increased investment in health R&D in Europe. The paper demonstrates that, even in 
times of austerity, policymakers need to prioritise approaches that will enhance public 
R&D investments and adopt strategies that produce incentives for private enterprises 
so that the current decline in private sector investment is halted.
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questions about priority and importance of certain outcome parameters like the 
thrombolysis rates vs. the independence of patients after 3 months. Finally, the com-
bination of MCDA and simulation modeling contributes to a transparent analytic 
process and results in a more complex understanding of the technology.
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Although the EU Council stated that “All health systems in the EU aim to make provision, 
which is patient-centered and responsive to individual need”, unacceptable differences in 
access to orphan medicinal products (OMP) in the Member States of the European 
Union are identified. In the context of the 2010 Belgian EU presidency initiative 
on ‘Innovation and Solidarity’ and within the framework of the process on corpo-
rate responsibility in the field of pharmaceuticals, EU Commissioner Tajani there-
fore launched the project Mechanism of Coordinated Access to OMP.Objectives: 
Designing a operational mechanism of coordinated access to OMP for patients, stake-
holders and Member States to provide, irrespective of the local conditions, access for 
patients with unmet medical needs and for whom these solutions would otherwise 
be out of reach – in an affordable and sustainable way (“real life access”). MethOds: 
The project is managed by Belgium (NIHDI), supported by the European Commission 
and Eminet. Thirteen Member States participated, with the stakeholders (AIM, EPF, 
ESIP, Eurordis, CPME, EFPIA, EGA, EuropaBio, GIRP). Three Workpackages cover the 
different aspects of granting effective access to medicines: Identifying and assess-
ing a relevant orphan drug (assessment/evaluation) - Selection of target population 
and mechanisms of funding (structural access) - Treatment (individual access). 
Feasibility at present and opportunities for near future development of desirable 
activities were studied, and no-go solutions were documented and rejected in order 
to develop implementable scenarios for pilot projects and policy recommendations. 
Discussion: Although coordinated access at an European level will be organized on a 
voluntary basis, some sort of commitment from the participating partners is required. 
Moreover, it is crucial that the subsidiarity principle is not jeopardized or compro-
mised. Duplication of efforts will be avoided and previously made investments – in 
terms of financial and human resources, expertise and experience - (ex. by EUnet 
HTA, EMA COMP, EUCERD, CAVOD,…) will be valorized.
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Objectives: To look at the affordability of orphan medications across Europe and 
whether payer attitudes to high-price medications are changing in the face of ris-
ing health care expenditure and tighter budgets. MethOds: A detailed review of 
7 EU markets (France, Germany, Italy, The Netherlands, Poland, Spain, UK) looking 
at payer attitudes and funding decisions for key orphan drugs and the political, 
economic and societal impact of these. A key focus of the research was insight into 
payer attitudes towards the evidence base for the purpose of pricing negotiations 
and how anecdotal evidence, such as Patient Reported Outcomes (PROs) and patient 
case studies, have an impact on decision-making. Detailed research was also under-
taken to ascertain the pricing levels achieved for a number of orphan drugs across 
Europe looking at payer thresholds and the implications of these for the purpose 
of reimbursement. Results: The research demonstrates that there is considerable 
variation in pricing levels across the European markets and difference in payer 
attitudes towards the way orphan drugs are funded. Overcoming evidence chal-
lenges in orphan diseases remains a headache for payers and scepticism remains 
around dosing, innovation and whether approaches such as “coverage with evidence 
development” are adequate and/or sustainable in the long-term following initial 
approval. cOnclusiOns: The environment for orphan medicines in Europe is 
changing; and as the financial performance of European countries begins to diverge, 
so do attitudes towards the funding of orphan medicines. Orphan medicine prices 
are rarely justified on the basis of traditional cost-effectiveness thresholds and most 
markets still differentiate them from other pharmaceuticals. However, payers are 
afraid of uncertainty and, given the increasing number of orphan drugs and the 
often tentative evidence base at launch, may be forced by overwhelming financial 
necessity to make tougher decisions on funding.
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Decision making rules in health technology assessments are often based on a fixed 
willingness to pay threshold for the incremental cost effectiveness. This may be 
thought of as consistent with expected utility – with utility here defined in terms of 
Incremental Net Benefit (INB) – a combination of QALY gain and the threshold value. 
Alternative methods such as multi criteria decision analysis allow incorporation 
of other dimensions into the decision space. These seek to explore whether utility 
may be driven by factors other than simple QALY gain. Prospect theory suggests 
that decision makers are concerned in practice with the ‘size’ of a given decision. 
Also, they handle investment and disinvestment differently. In the Irish State, every 
new drug is examined. In order to look at actual decisions, lifetime QALY gains were 
extracted from completed economic evaluations submitted to the Irish health care 
payer. Total spend on these was calculated using a combination of the payer reim-
bursement database and predicted budget impact. Real choices indicate that where 
the budget impact is relatively small the drug is more likely to be reimbursed even 
with a comparatively small QALY gain. Technologies in areas of cancer and orphan 
diseases often lie outside of the threshold where a technology would be accepted. 
Decision makers are faced with choices with varying degrees of risk. Choices asso-
ciated with a low budget impact are deemed to be less risky. This is pragmatic; it 
